alexa Chimeric Antigen Receptor Therapy for B-cell Malignancies.
Oncology

Oncology

Journal of Immunooncology

Author(s): Porter DL, Kalos M, Zheng Z, Levine B, June C

Abstract Share this page

Abstract We presented data showing that the CART-19 cells expressing the 4-1BB signaling domain can have unprecedented and massive in-vivo expansion, traffic to tumor sites, persist long term in vivo, and induce rapid and potent anti-tumor activity in chemotherapy refractory CLL patients.
This article was published in J Cancer and referenced in Journal of Immunooncology

Relevant Expert PPTs

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords